Advanced search
Publication Cover
Journal of Medical Economics Volume 27, 2024 - Issue 1
Submit an article Journal homepage
1,108
Views
0
CrossRef citations to date
0
Altmetric
Cardiovascular

Assessment of clinical and economic impact of rivaroxaban plus aspirin vs. aspirin alone as a secondary prophylaxis in patients with chronic and symptomatic peripheral arterial disease in the United States

Anshul Shaha Evidera, Mumbai, India
,
Firas Dabbousb Evidera Inc., Bethesda, MD, USACorrespondence[email protected]
,
Surbhi Shahc Evidera Inc., Waltham, MA, USA
,
Veronica Ashtond Janssen Scientific Affairs LLC, Titusville, NJ, USA
&
Akshay Kharatd Janssen Scientific Affairs LLC, Titusville, NJ, USA
Pages 10-15 | Received 15 Sep 2023, Accepted 29 Nov 2023, Published online: 09 Dec 2023

References

  • Shu J, Santulli G. Update on peripheral artery disease: epidemiology and evidence-based facts. Atherosclerosis. 2018;275:379–381. doi: 10.1016/j.atherosclerosis.2018.05.033.
  • Zemaitis MR, Boll JM, Dreyer MA. Peripheral arterial disease. Treasure Island (FL): StatPearls; 2022.
  • Centers for Disease and Control (CDC). Peripheral Arterial Disease (PAD) December 19. 2022. https://www.cdc.gov/heartdisease/PAD.htm.
  • Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American heart association. Circulation. 2021;143(8):e254–e743. doi: 10.1161/CIR.0000000000000950.
  • Bauersachs R, Debus S, Nehler M, et al. A targeted literature review of the disease burden in patients with symptomatic peripheral artery disease. Angiology. 2020;71(4):303–314. doi: 10.1177/0003319719896477.
  • Mahoney EM, Wang K, Cohen DJ, et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008;1(1):38–45. doi: 10.1161/CIRCOUTCOMES.108.775247.
  • Yost ML. The high cost of peripheral artery disease and critical limb ischemia. J Arterial Venous Lymphatic Interv. 2021;1(1)
  • Yost ML. The real cost of peripheral artery disease. Atlanta (GA): The Sage Group; 2011.
  • Berger A, Simpson A, Bhagnani T, et al. Incidence and cost of major adverse cardiovascular events and major adverse limb events in patients with chronic coronary artery disease or peripheral artery disease. Am J Cardiol. 2019;123(12):1893–1899. doi: 10.1016/j.amjcard.2019.03.022.
  • Desai U, Kharat A, Hess CN, et al. Incidence of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. Ann Vasc Surg. 2021;75:217–226. doi: 10.1016/j.avsg.2021.02.025.
  • Bevan GH, Solaru KTW. Evidence-Based medical management of peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020;40(3):541–553. doi: 10.1161/ATVBAHA.119.312142.
  • Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994–2004. doi: 10.1056/NEJMoa2000052.
  • Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330. doi: 10.1056/NEJMoa1709118.
  • Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229. doi: 10.1016/S0140-6736(17)32409-1.
  • Hernandez L, Shah A, Zhao Q, et al. Economic implications of preventing major cardiovascular and limb events with rivaroxaban plus aspirin in patients with coronary or peripheral artery disease in the United States. Am Health Drug Benefits. 2020;13(5):184–190.
  • Anand SS, Eikelboom JW, Dyal L, et al. Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial. J Am Coll Cardiol. 2019;73(25):3271–3280. doi: 10.1016/j.jacc.2019.02.079.
  • IBM Micromedex®. RED BOOK®. 2022. https://www.ibm.com/watson-health/about/micromedex.
  • US Bureau of Labor Statistics. Consumer price index. January 2023 CPI weight update Washington, DC. 2022. https://www.bls.gov/cpi/.
  • Mauskopf J, Earnshaw S. A methodological review of US budget-impact models for new drugs. Pharmacoeconomics. 2016;34(11):1111–1131. doi: 10.1007/s40273-016-0426-8.
  • Ollendorf D, McQueen R, Campbell J, et al. Additive therapies for cardiovascular disease: effectiveness and value. ICER. 2019.
  • Banerjee S. New developments in antiplatelet therapies for patients with peripheral artery disease. Am Coll Cardiol. 2016;22.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.